



PATENT
Customer No. 22,852
Attorney Docket No. 08201.0024-01000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

MACKAY et al.

Application No.: 10/045,574

Filed: November 7, 2001

For: BAFF, INHIBITORS THEREOF
AND THEIR USE IN THE
MODULATION OF B-CELL
RESPONSE AND TREATMENT
OF AUTOIMMUNE DISORDERS

)
)
) Group Art Unit: 1644

)
) Examiner: M. Haddad

PHB
RECEIVED

APR 28 2003

TECH CENTER 1600/2900

Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents were previously submitted in a prior application, application no. 09/911,777, filing date July 24, 2001, upon which applicant relies for the benefits provided in 35 U.S.C. § 120.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated:

April 25, 2003


By:

Leslie A. McDonell

Leslie A. McDonell
Reg. No. 34,872

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

Atty. Docket No.	08201.0024-01000	Appln. No.	10/045,574
Applicant	MACKAY et al.		
Filing Date	November 7, 2001	Group:	1644

RECEIVED
 APR 28 2003
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue/Filing Date	Name	Class	Sub Class	Filing Date If Appropriate
		6,475,986 B1	11/5/02	Aggarwal			
		6,475,987 B1	11/5/02	Shu			
		US 20030023038 A1	01-2003	Rennert et al.			

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or N
		WO 99/12964	3/18/99	PCT			
		WO 99/12965	3/18/99	PCT			
		WO 00/40716	7/13/00	PCT			
		WO 00/43032	7/27/00	PCT			
		WO 00/50633	8/31/00	PCT			
		WO 00/68378	11/16/00	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	International Search Report, International Application No. PCT/US00/01788, mailed July 26, 2000
	Colman PM, "Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions" <i>Res. Immunol.</i> , 145:33-36 (1994)
	Gras et al., "BCMAp: An Integral Membrane Protein in the Golgi Apparatus of Human Mature B Lymphocytes" <i>Int'l Immunol.</i> , 7:1093-1106 (1995)
	Gross et al., "TACI and BCMA are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease" <i>Nature</i> , 404:995-999 (2000)
	Hahne et al., "APRIL, A New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth" <i>J. Exp. Med.</i> , 188:1185-1190 (1998)
	Harlow et al., <i>Antibodies A Laboratory Manual</i> , Cold Spring Harbor, New York: ColdSpring Harbor Laboratory Press, (1988)
	Khare et al., "Severe B Cell Hyperplasia and Autoimmune Disease TALL-1 Transgenic Mice" <i>PNAS</i> , 97:3370-3375 (2000)



INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08204-10024-01000	Appln. No.	10/045,574
Applicant	MACKAY et al.		
Filing Date	November 7, 2001	Group:	1644

RECEIVED
APR 28 2003
TECH CENTER 1000/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Kogan et al., "A Single Amino Acid Residue Can Determine the Ligand Specialty of E-Selectin" <i>J. Biol. Chem.</i> , 270:14047-55 (1995)
	Kwon et al., "Functions of Newly Identified Members of the Tumor Necrosis Factor Receptor/Ligand Superfamilies in Lymphocytes" <i>Curr. Opin. Immunol.</i> , 340-345 (1999)
	Laabi et al., "A New Gene, BCM, on Chromosome 16 is Fused to the Interleukin 2 Gene by a t(4;16) (q26;p13) Translocation in a Malignant T Cell Lymphoma" <i>EMBO Journal</i> , 11:3897-3904 (1992)
	Laabi et al., "The BCMA Gene, Preferentially Expressed During B Lymphoid Maturation, is Bidirectionally Transcribed" <i>Nucleic Acid Res.</i> , 22:1147-1154 (1994)
	Mackay et al., "Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations" <i>J. Exp. Med.</i> , 190:1697-1710 (1999)
	Maldry et al., "The Characterization of Murine BCMA Gene Defines it as a New Member of the Tumor Necrosis Factor Receptor Superfamily" <i>Int'l Immunol.</i> , 10:1693-1702 (1998)
	Mukhopadhyay et al., "Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue that Activates Apoptosis, Nuclear Factor-kappaB, and c-Jun NH2-Terminal Kinase" <i>J. Biol. Chem.</i> , 274:15978-15981 (1999)
	Moore et al., "BlyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator" <i>Science</i> , 285:260-263 (1999)
	Pitti et al., "Genomic Amplification of a Decoy Receptor for Fas Ligand in Lung and Colon Cancer" <i>Nature</i> , 396:699-703 (1998)
	Schneider et al., "BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth" <i>J. Exp. Med.</i> , 189:1747-1756 (1999)
	Shu et al., "B Cell Maturation Protein is a Receptor for the Tumor Necrosis Factor Family Member TALL-1" <i>PNAS</i> , 97:9156-9161 (2000)
	Thompson et al., "BAFF Interacts with the Orphan Receptor BCMA" <i>Scandinavian J. Immunol.</i> , 51:65 (2000)
	Thompson et al., "BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population" <i>J. Exp. Med.</i> , 192:129-135 (2000)
	Ward et al., "Blocking of Adhesion Molecules In Vivo as Anti-Inflammatory Therapy" <i>Ther. Immunol.</i> , 1:165-171 (1994)
	Ware CF, "APRIL and BAFF Connect Autoimmunity and Cancer" <i>J. Exp. Med.</i> , 192:F35-8 (2000)
	Xia et al., "TACI is a TRAF-Interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation" <i>J. Exp. Med.</i> , 192:137-143 (2000)



OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08291-0034-01000	Appln. No.	10/045,574
Applicant	MACKAY et al.		
Filing Date	November 7, 2001	Group:	1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Yu et al., "APRIL and TALL-1 and Receptors BCMA and TACI: System for Regulating Humoral Immunity" <i>Nature Immunol.</i> , 1:252-256 (2000)

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

RECEIVED
APR 28 2003
TECH CENTER 1600/2900